Failure to Improve the Oxygenation Index Is a Useful Predictor of Therapy Failure in Acute Respiratory Distress Syndrome Clinical Trials.
Pubmed ID: 26427588
Pubmed Central ID: PMC5224531
Journal: Critical care medicine
Publication Date: 01/01/2016
Affiliation: 1Division of Pulmonary Critical Care, Department of Medicine, Feinberg School of Medicine, Northwestern University, Chicago, IL.2Department of Preventive Medicine, Northwestern University, Feinberg School of Medicine, Chicago, IL.3Réanimation des Détresses Respiratoires et des Infections Sévères, Hôpitaux de Marseille, Hôpital Nord, Marseille, France.4Faculté de Médecine, Aix-Marseille Université, URMITE UMR CNRS 7278, Marseille, France.
MeSH Terms: Humans, Randomized Controlled Trials as Topic, Retrospective Studies, Predictive Value of Tests, Ventilators, Mechanical, Treatment Failure, Blood Gas Analysis, Oxygen, Respiratory Distress Syndrome
Grants: UL1 TR001422, I01 BX000201, P01HL071643, P01 HL071643
Authors: Go L, Budinger GR, Kwasny MJ, Peng J, Forel JM, Papazian L, Jain M
Cite As: Go L, Budinger GR, Kwasny MJ, Peng J, Forel JM, Papazian L, Jain M. Failure to Improve the Oxygenation Index Is a Useful Predictor of Therapy Failure in Acute Respiratory Distress Syndrome Clinical Trials. Crit Care Med 2016 Jan;44(1):e40-4.
- Acute Respiratory Distress Network (ARDSNet) Studies 01 and 03 Lower versus higher tidal volume, ketoconazole treatment and lisofylline treatment (ARMA/KARMA/LARMA)
- Acute Respiratory Distress Network (ARDSNet) Study 04 Assessment of Low tidal Volume and elevated End-expiratory volume to Obviate Lung Injury (ALVEOLI)
- Acute Respiratory Distress Network (ARDSNet) Study 05 Fluid and Catheter Treatment Trial (FACTT)
OBJECTIVE: Acute respiratory distress syndrome trials powered for mortality require significant resources, limiting the number of evaluable therapies. Validation of intermediate endpoints would enhance the feasibility of testing novel acute respiratory distress syndrome therapies in pilot studies and potentially reduce the frequency of failed large clinical trials. We sought to determine whether a change in the oxygenation index over the first 7 days of acute respiratory distress syndrome could discriminate between therapies likely or unlikely to show benefit in larger clinical trials. DESIGN: A derivation cohort from three acute respiratory distress syndrome studies was used to estimate the 7-day change in oxygenation index. Receiver operating characteristic curves were used to calculate optimal thresholds and predictability of the change in oxygenation index for 28-day mortality and ventilator-free days. The thresholds were then validated in two cohorts. Then, for each individual acute respiratory distress syndrome study, the threshold 7-day oxygenation index change was tested as an outcome measure and compared with mortality and ventilator-free days as reported in the original study. SETTING: Medical ICUs. PATIENTS: Acute respiratory distress syndrome patients. INTERVENTIONS: Various. MEASUREMENTS AND MAIN RESULTS: Change in oxygenation index, 28-day mortality, and ventilator-free days. In the derivation cohort, the mean 7-day oxygenation index improved by 4.2 (± 11.7) in 28-day survivors compared with an increase of 2.4 (± 11.6) in 28-day nonsurvivors (p < 0.001). The mean 7-day oxygenation index decreased by 5.9 (± 8.4) in patients with more than 14 ventilator-free days, compared with a decrease of 1.9 (± 12.4) among those with less than 14 ventilator-free days (p = 0.001). The optimal 7-day oxygenation index threshold for predicting mortality was an increase of 1.71 and for predicting less than 14 ventilator-free days, a decrease of 2.34. When used as a surrogate endpoint, the optimal 7-day oxygenation index change closely approximated mortality and ventilator-free day outcomes in three Acute Respiratory Distress Syndrome Network studies used for the derivation cohort and a distinct study used for validation. The change in oxygenation index was a poor predictor of individual patient outcome. CONCLUSIONS: Failure to meet a threshold improvement in the oxygenation index over the first 7 days of therapy can be used to identify therapies unlikely to succeed in subsequent trials powered for mortality and ventilator-free days. By reducing trial time and costs, use of the 7-day oxygenation index change as an intermediate endpoint could increase the number of clinical trials of promising therapies for acute respiratory distress syndrome and reduce the number of large-scale trials of therapies unlikely to be of benefit.